mRNA-4106 / Moderna - LARVOL DELTA

A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Recruiting

Enrollment open • Colon Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Rectal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Moderna Science Day Highlights Expanding Potential of mRNA Platform (Investing News Network (INN)) - "Early Pipeline Progress: The Phase 1 study is ongoing with mRNA-4106 as monotherapy in advanced solid tumors...mRNA-4359 (Cancer antigen therapy): Designed to elicit T-cell immune responses against tumor and immunosuppressive cells, the Phase 1/2 study is ongoing with the Phase 2 portion including cohorts in first-line metastatic melanoma and first-line metastatic non-small cell lung cancer (NSCLC)....mRNA-2808 (T-cell engager): Designed to use multiplexed T-cell engagers to improve efficacy and overcome mechanisms of resistance for multiple myeloma, the Phase 1/2 study is ongoing and includes three distinct T-cell engagers against clinically validated targets....mRNA-2151 (T-cell engager)....this preclinical multiplexed T-cell engager program is moving toward early development in ovarian cancer."

Preclinical • Trial status • Melanoma • Multiple Myeloma • Non Small Cell Lung Cancer • Ovarian Cancer • Solid Tumor

A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=42 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: Jan 2029 ➔ Aug 2027 | Trial primary completion date: Jan 2029 ➔ Aug 2027

Trial completion date • Trial primary completion date • Colon Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Rectal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=57 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Checkpoint inhibition • Enrollment closed • Colon Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Rectal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • BRAF

Preclinical proof-of-concept of an off-the-shelf mRNA cancer antigen therapy targeting pan-tumor antigens for the treatment of multiple solid tumors (SITC 2025) - "Moderna's optimized antigen sequences enhanced tumor control and survival in a surrogate cancer model compared to wild-type sequences. Collectively, these findings establish preclinical proof-of-concept for mRNA-4106, supporting its potential as a broadly applicable, off-the-shelf mRNA cancer antigen therapy.Ethics Approval All animal experiments described in this study report were approved and conducted in accordance with the regulations of the Institutional Animal Care and Use Committee (IACUC Protocol 23-06-007)"

Pan tumor • Preclinical • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HLA-A

START Doses First U.S. Patient in Moderna's Phase 1 Clinical Trial of mRNA-4106, a Pan-Tumor Antigen Therapy Candidate, in Solid Tumors (PRNewswire) - "The START Center for Cancer Research...today announced the dosing of the first U.S. participant in Moderna's Phase 1 study evaluating mRNA-4106, a novel Pan-Tumor Antigen Therapy candidate, in patients with advanced or metastatic solid tumors."

Trial status • Solid Tumor

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=57 | Recruiting | Sponsor: ModernaTX, Inc. | Not yet recruiting ➔ Recruiting

Checkpoint inhibition • Enrollment open • Oncology • Solid Tumor

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=57 | Not yet recruiting | Sponsor: ModernaTX, Inc.

Checkpoint inhibition • New P1 trial • Oncology • Solid Tumor

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=57 | Not yet recruiting | Sponsor: ModernaTX, Inc.

Checkpoint inhibition • New P1 trial • Oncology • Solid Tumor